UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

Form 6-K

 

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2015

Commission File Number                         

 

 

Novogen Limited

(Translation of registrant’s name into English)

 

 

16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia

(Address of principal executive office)

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  þ             Form 40-F   ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ¨

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ¨

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes  ¨     No  þ

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)

 

 

 


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novogen Limited (Registrant)

Lionel Mateo

Lionel Mateo

Company Secretary

Date 25 September 2015


Appendix 3Y

Change of Director’s Interest Notice

 

 

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

 

Name of entity  Novogen Limited (“Novogen”)
ABN  37 063 259 754

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

 

Name of Director

 

   Mr Iain Ross

Date of last notice

 

  

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Direct or indirect interest    Direct

Nature of indirect interest

(including registered holder)

Note: Provide details of the circumstances giving rise to the relevant interest.

  
Date of change   

A.     18 September 2015

 

B.     21 September 2015

No. of securities held prior to change    0
Class   

Ordinary shares

Number acquired   

A.     100,000 ordinary shares

 

B.     100,000 ordinary shares

Number disposed    N/A
  

Value/Consideration

Note: If consideration is non-cash, provide details and estimated valuation

  

A.     $0.1635 per ordinary share

 

B.     $0.1674 per ordinary share

 

 

+ See chapter 19 for defined terms.

01/01/2011  Appendix 3Y  Page 1


Appendix 3Y

Change of Director’s Interest Notice

 

 

 

No. of securities held after change    200,000 ordinary shares

Nature of change

Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

   On market trade

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

 

Detail of contract   
Nature of interest   

Name of registered holder

(if issued securities)

  
Date of change   

No. and class of securities to which interest related prior to change

Note: Details are only required for a contract in relation to which the interest has changed

  
Interest acquired   
Interest disposed   

 

 

+ See chapter 19 for defined terms.

 

Appendix 3Y  Page 2    01/01/2011


Appendix 3Y

Change of Director’s Interest Notice

 

 

 

Value/Consideration

Note: If consideration is non-cash, provide details and an estimated valuation

 
Interest after change  

Part 3 – +Closed period

 

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?  
If so, was prior written clearance provided to allow the trade to proceed during this period?  
If prior written clearance was provided, on what date was this provided?  

 

 

+ See chapter 19 for defined terms.

01/01/2011  Appendix 3Y  Page 3

Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Kazia Therapeutics Charts.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Kazia Therapeutics Charts.